Abstract
Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Current Cancer Therapy Reviews
Title: Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Volume: 4 Issue: 2
Author(s): Dirk Schadendorf, Jochen Utikal, Balwir Matharoo-Ball, Robert C. Rees and Selma Ugurel
Affiliation:
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Abstract: Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Export Options
About this article
Cite this article as:
Schadendorf Dirk, Utikal Jochen, Matharoo-Ball Balwir, Rees C. Robert and Ugurel Selma, Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310061
DOI https://dx.doi.org/10.2174/157339408784310061 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Imaging Studies in Hypercalcemia
Current Medicinal Chemistry The Clustered DNA Lesions – Types, Pathways of Repair and Relevance to Human Health
Current Medicinal Chemistry Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy Empyema and Bronchopleural Fistula Following Lung Resection
Current Respiratory Medicine Reviews The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells
Medicinal Chemistry Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Current Pharmaceutical Design Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Current Molecular Pharmacology Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Gynaecological Cancer Diagnostics: 99mTc-Cisplatin Complex as a Future Approach for Early, Prompt and Efficient Diagnosis of Gynaecological Cancer
Current Medical Imaging Pathobiology of Head and Neck Squamous Tumorigenesis
Current Cancer Drug Targets Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
Anti-Cancer Agents in Medicinal Chemistry Proteomics on Fixed Tissue Specimens – A Review
Current Proteomics A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets HPV Viral Activity by mRNA-HPV Molecular Analysis to Screen the Transforming Infections in Precancer Cervical Lesions
Current Pharmaceutical Biotechnology Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets